AVROBIO (Nasdaq:AVRO) - Aandelenkoers, Nieuws & Analyse

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

AVRO Overzicht aandelen

A clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States.

Over het bedrijf

AVRO fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	3/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De koers-winstverhouding ( 24.9 x) ligt onder het gemiddelde van de Biotechs -industrie ( 18.6 x)

Dit jaar winstgevend geworden

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 18.4% per jaar dalen.

Grote eenmalige posten die de financiële resultaten beïnvloeden

Heeft geen betekenisvolle marktkapitalisatie ( $64M )

AVROBIO, Inc. Concurrenten

Spero Therapeutics

NasdaqGS:SPRO

US$66.5m

Eagle Pharmaceuticals

OTCPK:EGRX

US$5.2m

Protalix BioTherapeutics

NYSEAM:PLX

US$86.0m

CytomX Therapeutics

NasdaqGS:CTMX

US$77.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor AVROBIO
Historische aandelenkoersen
Huidige aandelenkoers	US$16.80
52 Week Hoogtepunt	US$19.80
52 Week Laag	US$10.56
Bèta	1.22
11 maand verandering	1.45%
3 maanden verandering	9.38%
1 Jaar Verandering	44.82%
33 jaar verandering	-85.45%
5 jaar verandering	-90.89%
Verandering sinds IPO	-95.51%

Recent nieuws en updates

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

Rendement voor aandeelhouders

	AVRO	US Biotechs	US Markt
7D	-4.8%	0.5%	0.5%
1Y	44.8%	24.7%	36.8%

Rendement versus industrie: AVRO overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 24.7 % opleverde.

Rendement versus markt: AVRO overtrof de US markt, die het afgelopen jaar een rendement opleverde van 36.8 %.

Prijsvolatiliteit

Is AVRO's price volatile compared to industry and market?
AVRO volatility
AVRO Average Weekly Movement	5.6%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: AVRO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van AVRO is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	13	Erik Ostrowski	www.avrobio.com

AVROBIO, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van AVROBIO zich tot de beurswaarde?
AVRO fundamentele statistieken
Marktkapitalisatie	US$63.75m
Inkomsten(TTM)	US$30.31m
Inkomsten(TTM)	n/a

24.9x

Koers/Winstverhouding

0.0x

P/S-verhouding

Is AVRO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AVRO resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	-US$30.31m
Inkomsten	US$30.31m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.68
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde AVRO op de lange termijn?

Bekijk historische prestaties en vergelijking

This company is no longer active

AVRO Overzicht aandelen

Beloningen

Risicoanalyse

AVROBIO, Inc. Concurrenten

NasdaqGS:SPRO

US$66.5m

OTCPK:EGRX

US$5.2m

NYSEAM:PLX

US$86.0m

NasdaqGS:CTMX

US$77.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline